Follicular lymphoma
Therapeutic area
Hematology
Rare disease
Yes
- Definition
- Follicular lymphoma is a form of non-Hodgkin lymphoma characterized by a proliferation of B cells whose nodular structure of follicular architecture is preserved.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Follicular lymphoma
- Therapeutic area
- Hematology
- follicular lymphoma
- follicle center lymphoma
- follicle centre lymphoma
- follicular center cell lymphoma
- follicular centre cell lymphoma
- follicular non-Hodgkin lymphoma
- follicular non-Hodgkin's lymphoma
- lymphoma, follicular center cell
- lymphoma, follicular centre cell
- lymphoma, follicular, malignant
- lymphoma, follicular
- Severity
- Severe
- Hematology
- Immunology
- Oncology
- MONDO ID
- MONDO:0018906
- Parent condition
- MONDO:0004949
Related records
Broader conditions (20)
- B-cell neoplasm
- B-cell non-Hodgkin lymphoma
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Immune system disorder
- Indolent B-cell non-Hodgkin lymphoma
- Leukocyte disorder
- Lymphoid hemopathy
- Lymphoid neoplasm
- Lymphoma
- Neoplasm
- Neoplasm of mature B-cells
- Neoplastic disease or syndrome
- Non-Hodgkin lymphoma
Trials (1,866)
- "MIRO" Molecularly Oriented Immuno-radio-therapy
- (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
- 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma
- 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
- 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
- 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
- 18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
- 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
- 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
- 5HTP Regulation Of Asthma In Children
- 64Cu-LLP2A for Imaging Hematologic Malignancies
- A Brief Negotiation Interview Chatbot to Improve Buprenorphine Engagement Among Justice-Involved Individuals
Approved drugs (12)
- Axicabtagene ciloleucel
- Copanlisib hydrochloride
- Duvelisib
- Duvelisib monohydrate
- Epcoritamab
- Interferon alfa-2B
- Lenalidomide hydrochloride monohydrate
- Mosunetuzumab
- Obinutuzumab
- Tazemetostat hydrobromide
- Umbralisib tosylate
- Yttrium Y 90 ibritumomab tiuxetan
Drugs in development (146)
- Abexinostat Phase 2
- Acalabrutinib Phase 2
- Acetaminophen Phase 2
- Agatolimod sodium Phase 2
- Aldesleukin Phase 3
- Alisertib Phase 1
- Allicin Phase 2
- Alvocidib hydrochloride Phase 1
- Amdizalisib Phase 2
- Apolizumab Phase 1
- Atezolizumab Phase 2
- Avadomide Phase 1
- Avelumab Phase 1
- Azacitidine Phase 2
- Belinostat Phase 1
- Bendamustine Phase 3
- Bendamustine hydrochloride Phase 2
- Bevacizumab Phase 3
- Bortezomib Phase 2
- Bortezomib D-mannitol Phase 2
Other linked drugs (1)
- Orvacabtagene autoleucel